Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial.

Ann Oncol · 2018 · PMC5913649 · PMID 29360932

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a positive trendno p-value reported

Time to deterioration analyses An analysis of TTD in FACT-B showed a positive trend (HR < 1) favoring the palbociclib plus letrozole arm but was not statistically significant [HR: 0.883 (95% CI 0.673−1.158); one-sided P =0.1900].

also in 11,005 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.